Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in RCC
NCT02212730Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2014
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in renal cell carcinoma (RCC) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With an Adverse Event, Number of Participants Who Discontinued Treatment Due to an Adverse Event up to 56 weeks and 3 more. Started Dec 2014; status: terminated.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02212730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212730.